Drugs Made In America Acquisition Corp. financial data

Symbol
DMAA, DMAAR, DMAAU on Nasdaq
Location
2 Pelican Dr., Fort Lauderdale, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.5M shares
Common Stock, Shares, Outstanding 10.5M shares
Common Stock, Value, Issued 1.05K USD

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 132K USD +140%
Operating Income (Loss) -132K USD -140%
Nonoperating Income (Expense) 2.42M USD
Net Income (Loss) Attributable to Parent 2.29M USD

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 49.7K USD
Assets 235M USD
Accrued Liabilities, Current 147K USD
Liabilities, Current 301K USD
Liabilities 7.2M USD
Retained Earnings (Accumulated Deficit) -6.46M USD
Stockholders' Equity Attributable to Parent -7.15M USD -35782%
Liabilities and Equity 235M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -251K USD
Net Cash Provided by (Used in) Financing Activities 231M USD
Net Cash Provided by (Used in) Investing Activities -231M USD
Common Stock, Shares Authorized 220M shares
Common Stock, Shares, Issued 10.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 822 USD -95.5%
Preferred Stock, Shares Authorized 1M shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares